SFI
GRTX

Susquehanna Fundamental Investments’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,186
Closed -$15.2K – 1146
2022
Q4 		$15.2K Sell
10,186
-4,814
-32% -$7.81K ﹤0.01% 1160
2022
Q3 		$26K Buy
+15,000
New +$21.2K ﹤0.01% 1396
2022
Q1 		$36K Buy
+15,000
New +$39.1K ﹤0.01% 1501

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Susquehanna Fundamental Investments's GRTX Position: Q1 2023 in Review

Susquehanna Fundamental Investments sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q1 2023, closing a stake of 10,186 shares — an estimated $15.2K sold.

Susquehanna Fundamental Investments first reported a position in GRTX in Q1 2022 and held it in 3 quarters. The position peaked at $36K in Q1 2022. 40 funds tracked by Wall St. Rank hold GRTX as of Q1 2023.

  • Susquehanna Fundamental Investments reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 10,186 Galera Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $15.2K.
  • Susquehanna Fundamental Investments first reported a position in Galera Therapeutics, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Galera Therapeutics, Inc. Common Stock position peaked at $36K in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2023, filed 16 May 2023.